

Yuichiro Tada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2471128/publications.pdf>

Version: 2024-02-01

56
papers

1,325
citations

430442

18
h-index

360668

35
g-index

58
all docs

58
docs citations

58
times ranked

1144
citing authors

#	ARTICLE	IF	CITATIONS
1	A multi-institutional study of salivary gland cytopathology: Application of the Milan System for Reporting Salivary Gland Cytopathology in Japan. <i>Cancer Cytopathology</i> , 2022, 130, 30-40.	1.4	14
2	Salivary mucoepidermoid carcinoma: histological variants, grading systems, <i>CRTC1/3-MAML2</i> fusions, and clinicopathological features. <i>Histopathology</i> , 2022, 80, 729-735.	1.6	14
3	Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2022, 42, 1607-1613.	0.5	1
4	How to dissect the para-hyoid lymph nodes for tongue cancer. <i>Japanese Journal of Head and Neck Cancer</i> , 2022, 48, 14-20.	0.0	0
5	A Study of Laryngectomy with Hyoid Bone Preservation Performed at Our Center. <i>Journal of Japan Society for Head and Neck Surgery</i> , 2022, 32, 1-7.	0.0	0
6	Yatagarasu: A single-arm, open-label, phase 2 study of apalutamide (APA) plus goserelin (GOS) for patients (pts) with far locally advanced or recurrent/metastatic (fLA/RM) and androgen receptor (AR)-expressing salivary gland carcinoma (SGC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 6079-6079.	0.8	1
7	Resection of Parapharyngeal Space Tumors Located in the Prestyloid Compartment: Efficacy of the Cervical Approach. <i>Annals of Surgical Oncology</i> , 2021, 28, 3066-3072.	0.7	6
8	The Diagnostic Utility of RAS Q61R Mutation-specific Immunohistochemistry in Epithelial-Myoepithelial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 885-894.	2.1	21
9	Sialadenoma Papilliferum of the Bronchus. <i>American Journal of Surgical Pathology</i> , 2021, 45, 662-671.	2.1	9
10	Pathological evaluation of tumor grade for salivary adenoid cystic carcinoma: A proposal of an objective grading system. <i>Cancer Science</i> , 2021, 112, 1184-1195.	1.7	19
11	Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade. <i>Cancers</i> , 2021, 13, 3527.	1.7	10
12	The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 779882.	1.3	7
13	Histopathological evaluation of minor salivary gland papillary-cystic tumours: focus on genetic alterations in sialadenoma papilliferum and intraductal papillary mucinous neoplasm. <i>Histopathology</i> , 2020, 76, 411-422.	1.6	39
14	Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 526-535.	2.1	10
15	A novel technique of arterial blood flow modification in intra-arterial chemoradiotherapy of maxillary sinus squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 109, 104873.	0.8	0
16	Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. <i>Scientific Reports</i> , 2020, 10, 16988.	1.6	32
17	Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients. <i>Cancers</i> , 2020, 12, 3427.	1.7	17
18	Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 89, 102069.	3.4	32

#	ARTICLE	IF	CITATIONS
19	Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma. <i>Anticancer Research</i> , 2020, 40, 5277-5283.	0.5	24
20	Prognostic impact of CRTC1/3â€MAML2 fusions in salivary gland mucoepidermoid carcinoma: A multiinstitutional retrospective study. <i>Cancer Science</i> , 2020, 111, 4195-4204.	1.7	20
21	Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>In Vivo</i> , 2020, 34, 2653-2657.	0.6	7
22	Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment. <i>Cancer Cytopathology</i> , 2020, 128, 693-703.	1.4	63
23	Clinicopathological significance of <i>EGFR</i> pathway gene mutations and <i>CRTC1/3â€MAML2</i> fusions in salivary gland mucoepidermoid carcinoma. <i>Histopathology</i> , 2020, 76, 1013-1022.	1.6	11
24	The impact of clinicopathological factors on clinical outcomes in patients with salivary gland adenoid cystic carcinoma: a multi-institutional analysis in Japan. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1774-1785.	1.0	19
25	The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 291-299.	1.4	7
26	Central pathology review of salivary gland adenoid cystic carcinoma. <i>Head and Neck</i> , 2020, 42, 1721-1727.	0.9	11
27	Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients. <i>Cancer Medicine</i> , 2020, 9, 5015-5024.	1.3	28
28	A Case of Cervical Lymph Node Metastasis from a p16-Positive Unknown Primary Cancer Diagnosed by Needle Biopsy. <i>Practica Otologica</i> , 2020, 113, 569-573.	0.0	0
29	ADC histogram analysis of MR imaging in the different diagnosis between benign and malignant tumors in the parapharyngeal space. <i>Japanese Journal of Head and Neck Cancer</i> , 2020, 46, 248-253.	0.0	0
30	Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study. <i>In Vivo</i> , 2019, 33, 843-853.	0.6	19
31	Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2â€Positive Salivary Duct Carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 125-134.	0.8	157
32	Venous malformation of the parapharyngeal space: Two surgical case reports and a literature review. <i>Otolaryngology Case Reports</i> , 2019, 13, 100130.	0.0	3
33	Diagnostic Significance of HRAS Mutations in Epithelial-Myoepithelial Carcinomas Exhibiting a Broad Histopathologic Spectrum. <i>American Journal of Surgical Pathology</i> , 2019, 43, 984-994.	2.1	63
34	Classification of tumors by imaging diagnosis and preoperative fineâ€needle aspiration cytology in 120 patients with tumors in the parapharyngeal space. <i>Head and Neck</i> , 2019, 41, 1277-1281.	0.9	23
35	An attempt at scoring laryngeal findings for cannula replacement after head and neck cancer reconstructive surgery. <i>Japanese Journal of Head and Neck Cancer</i> , 2019, 45, 310-313.	0.0	0
36	What is the best way of resection for subtotal glossectomy?. <i>Journal of Japanese Society of Oral Oncology</i> , 2019, 31, 181-189.	0.0	0

#	ARTICLE	IF	CITATIONS
37	A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. <i>Annals of Oncology</i> , 2018, 29, 979-984.	0.6	146
38	Postoperative radiotherapy for T1/2N0M0 mucoepidermoid carcinoma positive for CRTCl/3MAML2 fusions. <i>Head and Neck</i> , 2018, 40, 2565-2573.	0.9	8
39	Mutation analysis of the EGFR pathway genes, <i>EGFR</i> , <i>RAS</i> , <i>PIK3CA</i> , <i>BRAF</i> , and <i>AKT1</i> , in salivary gland adenoid cystic carcinoma. <i>Oncotarget</i> , 2018, 9, 17043-17055.	0.8	17
40	The high expression of <i>FOXA1</i> is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases. <i>Histopathology</i> , 2018, 73, 943-952.	1.6	9
41	Efficacy and safety of a vessel sealing system in oral cancer resection and reconstructive surgery. <i>Acta Oto-Laryngologica</i> , 2018, 138, 759-762.	0.3	6
42	Novel approach for unresectable salivary duct carcinoma: Targeting HER2 and androgen receptor.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6084-6084.	0.8	1
43	Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas. <i>Oncotarget</i> , 2018, 9, 1852-1867.	0.8	39
44	A clinical analysis of 45 operation cases of pleomorphic adenoma occurred in parapharyngeal space. <i>Journal of Japan Society for Head and Neck Surgery</i> , 2017, 27, 53-59.	0.0	1
45	A study of 12 cases of submandibular gland carcinoma. <i>Journal of Japan Society for Head and Neck Surgery</i> , 2017, 27, 67-72.	0.0	1
46	Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan. <i>Oncotarget</i> , 2017, 8, 1083-1091.	0.8	23
47	Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification. <i>Oncotarget</i> , 2017, 8, 59023-59035.	0.8	79
48	Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy. <i>International Cancer Conference Journal</i> , 2016, 5, 150-153.	0.2	4
49	Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients. <i>Annals of Surgical Oncology</i> , 2016, 23, 2038-2045.	0.7	80
50	Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. <i>International Journal of Clinical Oncology</i> , 2015, 20, 35-44.	1.0	94
51	Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma. <i>Oncology Letters</i> , 2012, 4, 898-904.	0.8	1
52	Sebaceous Carcinoma of the Parotid Gland. <i>Clinical Nuclear Medicine</i> , 2010, 35, 260-262.	0.7	10
53	Phosphorylation of influenza C virus CM2 protein. <i>Virus Research</i> , 1998, 58, 65-72.	1.1	15
54	Evolutionary analysis of influenza C virus M genes. <i>Virus Genes</i> , 1997, 15, 53-59.	0.7	27

#	ARTICLE	IF	CITATIONS
55	Facial Nerve Enhancement in Gd-MRI in Patients with Bell's palsy. Acta Oto-Laryngologica, 1994, 114, 165-169.	0.3	45
56	Gd-DTPA Enhanced MRI in Ramsay Hunt Syndrome. Acta Oto-Laryngologica, 1994, 114, 170-174.	0.3	28